Given that ITGA3 levels remain primarily unaffected by tumor progression, it could serve as a dependable biomarker for prognosis, particularly within specific BC subtypes, such as ER-positive, Luminal A, and Luminal B subtypes. The gene discussed is ESR1; the disease is breast cancer.